Saturday, April 20, 2013

Madocoit: a runaway smash hit with lesbian couples

Madocoit: a runaway smash hit with lesbian couples

October 26, 2027

Weekly Report Posted: November 17, 2012 18:40

Madocoit, the artificial conception drug, has been in use for many years and has resulted in many happy lesbian couple forming happy, prosperous families. Madocoit was developed by two Mitakihara University students now practicing doctor, Taiwanese-born Dr. Wong Bu Hao and Dr. Wong Long Dong, both twins from Kaohsiung.

"We developed Madocoit as a way to turn IPS cells into embryos that can develop into a proper baby," said Bu Hao in an interview from his office in downtown Victoria. "A woman involved in a lesbian relationship does not orally ingest this drug. This is an IPS cell programmed to be inserted inside the woman's vagina, where it will make its way down the fallopian tube.

"Then, she and her partner will need to engage in three hours of tribadism in order to stimulate the newly-inserted IPS cell so that it can fertilize and become a fertized egg, similar to that created and man and a woman.

"Madocoit is not artificial sperm. This is IPS cells at work, while eliminated the need for artificial sperm. With Madocoit, sperm donations will soon wander into obscurity faster than you think."

"Another thing about Madocoit is that it can only be used once every 12 months," said Long Dong from his office in Langley. "After the conception process concludes, three months must pass for the body to properly recover.

"If a female patient takes Madocoit again inside the 12-month window after the conception process concludes, the resulting fetus will result in a stillbirth and the patient risks accelerated menopause, infertility and/or sterility for life."

Thanks to proper use of the IPS cell drug Madocoit, lesbian families have skyrockets by over 9,000 percent, according to reports from the Harvard Medical Review. No other side effects have been seen with this drug outside of the natural side effects that go with the conception process, making this safe to use. However, Madocoit can only be purchased through prescription. It is not an over-the-counter drug.

What is an IPS cell?
Induced pluripotent stem cells, commonly abbreviated as iPS cells or iPSCs are a type of pluripotent stem cell artificially derived from a non-pluripotent cell - typically an adult somatic cell - by inducing a "forced" expression of specific genes.

Induced pluripotent stem cells are similar to natural pluripotent stem cells, such as embryonic stem (ES) cells, in many aspects, such as the expression of certain stem cell genes and proteins, chromatin methylation patterns, doubling time, embryoid body formation, teratoma formation, viable chimera formation, and potency and differentiability, but the full extent of their relation to natural pluripotent stem cells is still being assessed.

iPSCs were first produced in 2006 from mouse cells and in 2007 from human cells in a series of experiments by Shinya Yamanaka's team at Kyoto University, Japan, and by James Thomson's team at the University of Wisconsin-Madison. For his iPSC research, Yamanaka was awarded the Wolf Prize in Medicine and the Nobel Prize in medicine in 2012 (along with John B. Gurdon). For his iPSC discovery (and for deriving the first human embryonic stem cell), James Thomson received the 2011 Albany Medical Center Prize for Biomedical Research and the 2011 King Faisal International Prize, which he shared with Yamanaka.

iPSCs are an important advance in stem cell research, as they may allow researchers to obtain pluripotent stem cells, which are important in research and potentially have therapeutic uses, without the controversial use of embryos. Because iPSCs are developed from a patient's own somatic cells, it was believed that treatment of iPSCs would avoid any immunogenic responses; however, Zhao et al. have challenged this assumption.

Depending on the methods used, reprogramming of adult cells to obtain iPSCs may pose significant risks that could limit their use in humans. For example, if viruses are used to genomically alter the cells, the expression of cancer-causing genes "oncogenes" may potentially be triggered. In February 2008, scientists announced the discovery of a technique that could remove oncogenes after the induction of pluripotency, thereby increasing the potential use of iPS cells in human diseases. In April 2009, it was demonstrated that generation of iPS cells is possible without any genetic alteration of the adult cell: a repeated treatment of the cells with certain proteins channeled into the cells via poly-arginine anchors was sufficient to induce pluripotency.The acronym given for those iPSCs is piPSCs (protein-induced pluripotent stem cells).

No comments:

Post a Comment